^
Association details:
| Biomarker: | KRAS mutation + PTPN11 overexpression + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
High SHP2 Expression Determines the Efficacy of PD-1/PD-L1 Inhibitors in Advanced KRAS Mutant Non-Small Cell Lung Cancer
Published date:
08/18/2021
Excerpt:
61 advanced KRAS mutant NSCLC patients treated with immunotherapy were enrolled. SHP2 was heterogeneously expressed in 32 samples and highly expressed (H-score>10) in 25 (78.1%) samples....Patients with high expression of both SHP2 and PD-L1 had a longer PFS (P < 0.001).
